Interferon-lambda Receptor Positive Monocytes/Macrophages Orchestrate a Pro-fibrotic Immune Environment in Hepatitis B Virus-Related Liver Fibrosis.
Abstract
Interferon-lambda receptor (IFNLR), a heterodimer composed of IFNLR1 and IL-10Rbeta, mediates IFN-lambda-driven fibrotic effects. This study investigated the involvement of IFNLR1+ monocytes/macrophages in orchestrating pro-fibrotic immune microenvironment. Flow cytometric analysis of peripheral blood showed that IFNLR1+ monocytes were elevated in patients with chronic hepatitis B virus (HBV) infection (CHI) and patients with HBV-related liver cirrhosis (LC), compared with healthy control (HC). These cells also displayed a CCR2hiCCR5hiCX3CR1hiCD86hiHLA-DRhiCD163hiMERTKhi phenotype with an IL-10hiTNF-alphahi cytokine profile. Hepatic fibrosis was induced in wild-type and Ifnlr1-knockout (Ifnlr1-/-) mice using carbon tetrachloride and recombinant adeno-associated virus 8-1.3HBV. Ifnlr1 deficiency downregulated CCR2 and CCR5 expression on monocytes/macrophages, attenuated collagen deposition, but enhanced HBV-DNA replication. In vitro, bone marrow derived macrophages (BMDMs) were co-cultured with hepatic stellate cells (HSCs) or naive CD4+ T cells to assess the functional impact of IFNLR1+ macrophages. Concurrently, the involvement of lipid metabolism in IFN-lambda/IFNLR1-mediated macrophage regulation was examined using liver X receptor (LXR) agonists/antagonists. Ifnlr1-/- BMDMs exhibited a diminished capacity to activate HSCs and drive regulatory T cells differentiation. Mechanistically, IFN-lambda-IFNLR1 signaling suppressed LXR-dependent lipid metabolism, thereby promoting tumor necrosis factor (TNF)-alpha and IL-1beta production, and LXR pathway inhibition favored M1-macrophage polarization. Collectively, IFNLR1 identifies a pro-fibrotic and immunoregulatory monocyte/macrophage subset. Targeting IFNLR1-LXR axis may represent promising anti-fibrotic strategies for HBV-related liver fibrosis.
| Authors: | Wang S, Li S, Zhang J, Liu Z, Zhu Y, Cheng L, Chen F, Shen Y, Wu J, Jiang W. |
|---|---|
| Journal: | Clin Sci (Lond) . 2026 Oct 14;140(10):2229-2247. doi: 10.1042/CS20261452. |
| Year: | 2026 |
| PubMed: | PMID: 42742113 (Go to PubMed) |